Clinical Trial Details
Braintumor Website

[Information provided by:, which provides patients, family members, and members of the public easy and free access to information on clinical studies for a wide range of diseases and conditions.]

NCT01849146 : Adavosertib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed or Recurrent Glioblastoma
PhasePhase 1
AgesMin: 18 Years Max: N/A
Inclusion Criteria:

- Patients must have a tumor tissue form indicating availability of archived tissue from
initial resection at diagnosis of glioblastoma completed and signed by a pathologist

- Patients must have a Karnofsky performance status >= 60% (i.e. the patient must be
able to care for himself/herself with occasional help from others)

- Absolute neutrophil count >= 1,500/mcL

- Platelets >= 100,000/mcL

- Hemoglobin >= 9 g/dL

- Total bilirubin =< institutional upper limit of normal

- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase
[SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT])
=< 3 x institutional upper limit of normal; if above the institutional upper limit of
normal but =< 3 times institutional upper limit of normal, the decision to initiate
temozolomide treatment should carefully consider the benefits and risks for the
individual patient

- Creatinine =< institutional upper limit of normal OR creatinine clearance >= 60
ml/min/1.73 m^2 for patients with creatinine levels above institutional normal

- Activated partial thromboplastin time (APTT)/partial thromboplastin time (PTT) =< 1.5
x institutional upper limit of normal

- Patients must be able to provide written informed consent

- Patients must have magnetic resonance imaging (MRI) within 21 days of starting

- Women of childbearing potential must have a negative serum pregnancy test prior to
study entry; women of childbearing potential and men must agree to use two birth
control methods (either two barrier methods or a barrier method plus a hormonal
method) or abstinence prior to study entry and for the duration of study
participation; should a woman become pregnant or suspect she is pregnant while
participating in this study, she should inform her treating physician immediately

- Patients must have no concurrent malignancy except curatively treated basal or
squamous cell carcinoma of the skin or carcinoma in situ of the cervix, breast, or
bladder; patients with prior malignancies must be disease-free for >= five years

- Patients must be maintained on a stable corticosteroid regimen (no increase for 5
days) prior to the start of treatment

- Patients must be able to swallow whole capsules


- Must have histologically proven glioblastoma

- Must have recovered from the immediate post-operative period

- Patients going on Arm 1 or combination dose cohort must not have received prior
radiation therapy, chemotherapy, immunotherapy or therapy with biologic agent
(including immunotoxins, immunoconjugates, antisense, peptide receptor antagonists,
interferons, interleukins, tumor infiltrating lymphocytes [TIL], lymphokine-activated
killer [LAK] or gene therapy), or hormonal therapy for their brain tumor;
glucocorticoid therapy is allowed

- Patients going on Arm 2 must have received planned treatment with radiation therapy
and concomitant temozolomide at least 28 days but no more than 49 days prior to
starting treatment on this study; patients must have received at least 80% of planned
temozolomide and radiation therapy with no grade 3 or grade 4 toxicity (except
lymphopenia) attributed to the temozolomide; Arm 2 patients may not have received any
other prior chemotherapy, immunotherapy or therapy with biologic agent (including
immunotoxins, immunoconjugates, antisense, peptide receptor antagonists, interferons,
interleukins, TIL, LAK or gene therapy), or hormonal therapy for their brain tumor;
prior Gliadel wafers are allowed; glucocorticoid therapy is allowed


- Patients must have prior histologically proven glioblastoma that is progressive or
recurrent following radiation therapy +/- chemotherapy

- Patients must be undergoing repeat surgery that is clinically indicated as determined
by their care providers

- Patients must have measurable contrast-enhancing progressive or recurrent glioblastoma
by MRI within 21 days of starting treatment; patient must be able to tolerate MRIs

- Patients may have an unlimited number of prior therapy regimens

- Patients must have recovered from severe toxicity of prior therapy; the following
intervals from previous treatments are required to be eligible:

- 12 weeks from the completion of radiation

- 6 weeks from a nitrosourea chemotherapy

- 3 weeks from a non-nitrosourea chemotherapy

- 4 weeks from any investigational (not Food and Drug Administration
[FDA]-approved) agents

- 2 weeks from administration of a non-cytotoxic, FDA-approved agent (e.g.,
Tarceva, hydroxychloroquine, bevacizumab, etc.)

Exclusion Criteria:

- Patients receiving any other investigational agents are ineligible

- Patients with a history of allergic reactions attributed to compounds of similar
chemical or biologic composition to temozolomide or AZD1775 (MK-1775) are ineligible;
the AZD1775 (MK-1775) investigator brochure and the temozolomide package insert can be
referenced for more information

- Patients on enzyme-inducing anti-epileptic drugs (EIAED) are not eligible for
treatment on this protocol; patients may be on non-enzyme inducing anti-epileptic
drugs or not be taking any anti-epileptic drugs; patients previously treated with
EIAED may be enrolled if they have been off the EIAED for 10 days or more prior to the
first dose of AZD1775 (MK-1775)

- Patients may not be on drugs known to be moderate or potent inhibitors/inducers of
CYP3A4, sensitive substrates of CYP3A4, or substrates of CYP3A4 with narrow
therapeutic windows

- Patients may not be on anti-coagulants (warfarin, etc.) other than low-molecular
weight heparin (LMWH)

- Patients with uncontrolled intercurrent illness including, but not limited to, ongoing
or active infection, symptomatic congestive heart failure, unstable angina pectoris,
cardiac arrhythmia, or psychiatric illness/social situations that would limit
compliance with study requirements, are ineligible

- Pregnant women are excluded from this study; breastfeeding should be discontinued if
the mother is treated with AZD1775 (MK-1775)

- Human immunodeficiency virus (HIV)-positive patients on combination antiretroviral
therapy are ineligible
LinksPermanent Link to THIS page:      |      Link to official listing

Home | Brain Tumor Guide | FAQs | Find A Treatment
Noteworthy Treatments | News | Virtual Trial | Videos | Novocure Optune® | Newsletter
Donations | Brain Tumor Centers | Survivor Stories | Temodar®
Fundraising For Research | Unsubscribe | Contact Us

Copyright (c) 1993 - 2020 by:
The Musella Foundation For Brain Tumor Research & Information, Inc
1100 Peninsula Blvd
Hewlett, NY 11557